Extracellular proteases are recognized as critical factors in the progression of a number of carcinomas, including prostate cancer. Matrix metalloproteases (MMP) are important in processes of tumor growth, invasion and dissemination, but other classes of proteases, such as serine and cysteine proteases, also contribute. We utilized the TRAMP model for prostate cancer to elucidate proteases involved in prostate cancer progression. General proteomic analysis was performed on normal murine prostate, early TRAMP tumors and advanced TRAMP tumors, as well as normal and involved lymph nodes. Zymography and antigenic analyses revealed increased expression of mainly pro-MMP in early TRAMP tumors but substantial elaboration of activated MMP only in late TRAMP tumors. Progressive increase in cysteine, serine and certain membrane-bound proteases from normal to early to advanced prostate tumors, was also seen. Our results implicate pericellular proteases as initiators of major proteolytic cascades during tumor progression and suggest targets for maximal therapeutic effect.
Introduction
Pericellular proteolysis is thought to be an important biochemical event in the progression of a variety of malignancies, including prostate cancer. Secreted or surface-bound proteases from tumor cells or stromal elements help mediate the crucial steps of tumor invasion, migration, metastasis and angiogenesis. 1 Increased expression of a number of different proteases has been reported in human prostate cancer (PCA). Elevated expression of several matrix metalloproteases (MMPs) has been noted in PCA cell lines and primary tumor specimens. 2 Certain preclinical studies have demonstrated significant inhibition of xenographic prostate tumor growth after treatment with an MMP inhibitor. 3 Serine protease production has long been associated with the urogenital tract and this class of proteases is important in prostate biology. The urokinase plasminogen activator (UPA) was originally isolated from human urine and is expressed in PCA specimens. 4 Prostatespecific antigen (PSA) is a kallikrein-like serine protease now widely accepted as a useful serum marker for PCA detection and monitoring. 5 Some investigators believe that PSA plays a direct role in modulating prostate cancer cell proliferation. 6 A number of more recently described serine proteases-pKS2, TMPRSS2, MT-SP1-have been implicated in PCA evolution, as well. [7] [8] [9] Clinical investigations of serum levels have also shown a significant association of the serine protease UPA and its receptor (UPAR) with PCA progression and prognosis. 10 Previous studies in our laboratory have shown pronounced disruption of PCA tumor growth and dissemination by antagonists of this serine protease system. 11 Recent studies by other groups also suggest a potential therapeutic role for serine protease inhibitors in PCA. 12 Although these reports on one or two individual proteases at discordant disease stages are informative, a broader characterization of proteases in PCA at the proteomic level from early to advanced stages has been lacking. The importance of a more generalized characterization is pointed up by the negative impact of selective protease inhibitors in recently reported human trials. 13 One hindrance to the elucidation of the role extracellular proteases play in prostate cancer has been the paucity of human tissue specimens available for such analysis. Although human tissue banks are being established for prostate cancer, the availability of specimens, from various stages for a variety of types of analyses, is still limited. Within the past 5 y, transgenic animal models have become available, which in many ways, closely mimic human adenocarcinoma of the prostate. We chose the TRAMP model developed by Greenberg et al.
14 to carry out a general characterization of protease expression at the protein level across a range of tumor tissue specimens, with a variety of techniques. We are also investigating its use as a preclinical model for evaluating novel protease inhibitors. Here we report our findings in TRAMP from zymography, immunohistochemistry (IHC), Western blotting, and fluorogenic substrate analyses. Our results show a general increase in overall proteolytic activity during tumor progression, especially in the metalloprotease and cysteine protease classes. However, particular species of proteases are modulated in alternate ways during tumorigenesis.
Experimental procedures Transgenic mice and normal murine tissue
Generation of early and late TRAMP. Female TRAMP mice were provided by NM Greenberg and crossed with normal, nontransgenic males to generate affected TRAMP males (C57BL6/FVBN mix). Progeny were screened for the PB-Tag transgene by polymerase chain reaction (PCR). Certain TRAMP males were allowed to develop only to about 15-16 weeks of age ('early TRAMP'), when they were euthanized and tissues harvested for analysis. Other transgenic males were allowed to mature and develop advanced pelvic tumors, with the mice generally killed in the 24-32 weeks of age range ('late TRAMP'), when they were in the terminal phase of malignancy. Normal murine tissues were obtained from C57BL6 males that were wild type and negative for the PB-Tag transgene.
Tissue harvesting. Tissues were dissected immediately and processed into tissue extracts, frozen sections with OCT, or formalin-fixed for subsequent paraffin embedding. Where possible, distinct lobes of the prostate (ventral, lateral, dorsal and anterior), as well as seminal vesicles, were isolated by microdissection. Abdominal and thoracic organs were surveyed grossly for metastatic deposits. Lymph nodes (LN) involved by metastases were generally evident due to their enlarged size and easy visibility.
Histology and immunohistochemistry. Polyclonal and monoclonal antibodies against murine proteases MMP-2, MMP-3, MMP-9, MT1-MMP were obtained commercially or through collaborators at the University of California San Francisco and Vanderbilt University. Polyclonal antibodies (anti-sera) against MT-SP1 were raised in rabbits via immunization with synthetic peptides as previously described. 15 Paraffin-embedded and frozen sections were cut on microtomes at 7-10 mm thickness. Paraffin sections were deparaffinized according to standard protocols. Frozen sections were generally fixed with paraformaldehyde and cold methanol with 0.3% H 2 O 2 for quenching of endogenous peroxidases. A volume of 5% goat serum in phosphate-buffered saline (PBS) was used as a blocking agent. Primary antibodies were incubated with specimens for 2-3 h; secondary antibody was usually an anti-IgG : biotin conjugate. Washings were carried out for 45-60 min with three changes of PBS. Detection was performed with streptavidin : horseradish peroxidase complex, using DAB or AEC with H 2 O 2 for substrates. Specimens were counterstained with hematoxylin alone or occasionally with hematoxylin plus eosin (H&E).
Western analysis. Freshly dissected or frozen tissue samples from normal organs, primary tumors, tumor metastases, or cell line pellets were homogenized to 4 mg/ml in ice-cold PBS with 0.1% Triton X-10. The homogenate was centrifuged briefly at 41C to remove insoluble cellular elements. Equal amounts of protein were loaded from different samples into the wells of 7.5-12.5% SDS-polyacrylamide gels. Prestained molecular weight standards were also included on all gel electrophoreses. Subsequent transfer of protein bands to Immobilon-P membranes (Millipore Corp., Bedford, MA) was usually carried out overnight at 41C. Membranes were blocked in a casein solution, then incubated with primary antibody, followed by incubation with secondary antibody conjugated directly or indirectly to peroxidase. Detection was carried out using ECL reagents (Amersham, Inc., Piscataway, NJ).
Protease activity assays
Tissue extracts. Freshly dissected tissues or, occassionally, frozen tissue samples from time-matched prostate cancer sets (tumor, adjacent normal tissue, and liver metastases stored at À701C), were homogenized to 4 mg/ml in ice-cold PBS with 0.1% Triton X-100 using a Tenbrock homogenizer on ice. The homogenate was centrifuged in a microfuge at 16 000 g for 10 min at 41C. Protein concentration was determined by Bradford analysis using a bovine serum albumin (BSA) standard (Bio Rad, Hercules, CA, USA). Pellets and aliquoted supernatants were stored at À701C.
Protease activity assays. Fluorogenic peptide substrates were used to assay the activity in the tissue extracts and control conditioned media. Release of fluorescent product was followed at room temperature with a 96-well fluorometric plate reader (Fluoroskan II, LabSystems, Franklin, MA, USA).
General cysteine protease activity was assayed (ex 366, em 405) in 100 mM Na acetate, pH 6.5, containing 10 mM DTT (Buffer A) using either Cbz-Phe-Arg_AMC or Patterns of protease production RA Bok et al Cbz-Arg-Arg-AMC at 20 mM (Bachem (King of Prussia, PA, USA) from 10 mM stocks in dimethylsulfoxide (DMSO)). Controls of extract buffer alone, bovine cathepsin B (Sigma, St Louis, MO, USA) and recombinant cruzain (a cathepsin-L-like protease) were included. Specificity of activity was tested by preincubating samples for 30 min at room temperature with the general cysteine protease inhibitor E64 (Sigma; 20 mM stock in DMSO) at 10 mM, or the specific cathepsin B inhibitor CA-074 (a gift of Taisho Pharmaceutical Co., Ltd (Santama, Japan); 200 mM stock in DMSO) at 1 mM, or DMSO at equivalent % (volume per volume, v/v) alone.
General serine protease activity was assayed in 50 mM Tris-HCl, pH 8.2, 150 mM NaCl, 5 mM CaCl 2 (Buffer B) using 100 mM Cbz-Arg-Arg-AMC. Specificity of activity was determined by preincubating the samples for 30 min in 1 mM phenylmethylsulfonyl fluoride (PMSF) (100 mM stock in DMSO, Sigma), 10 mM E64 or DMSO alone. UPA activity was assayed with 20 mM glutaryl-Gly-Arg-AMC (Bachem) in 50 mM Tris, pH 8.8, 50 mM NaCl with 0.01% Tween 80. Controls of human high molecular weight UPA (American Diagnostics, Greenwich, CT, USA), and conditioned media from a human prostate cell line (PC3) were included. PSA-like activity was assayed with 200 mM morpholine carboxyl-His-Ser-Ser-Lys-Leu-Gln-AMC (20 mM stock in DMSO, Enzyme Systems Products, Livermore, CA, USA) in Buffer B. Specificity of activity was determined by preincubating samples with PMSF and E64 inhibitors (as described above).
MMP activity for MMP-1 (collagenase I) and MMP-9 (gelatinase B) was assayed with 5 mM DNP-pro-betacyclohexyl-Ala-Gly-Cys(Me)-His-Ala-Lys-(N-Me-Abz)-NH2 (ex 365, em 450; 10 mM stock in DMSO; Bachem) in Buffer B. Cytotrophoblast CM (CTB CM) was used as an activity control.
Zymography. Protease activity was detected in 10-15 ml samples from extracts, following separation on SDSpolyacrylamide mini-gels copolymerized with 1 mg/ml type I gelatin or 1 mg/ml casein (Novex, Carlsbad, CA). Plasminogen activator acitivity was determined on zymograms copolymerized with 1 mg/ml casein (Sigma) and 13 mg/ml plasminogen (American Diagnostics). After electrophoresis, zymogram gels were washed two times for 15 min in 2.5% Triton X-100 to reactivate enzymes by removal of SDS. Gels were rinsed for 30 min in developing buffer from Novex, followed by 15-24 h incubation at 371C on a rocking platform in developing buffer. Developing buffer consisted of 50 mM Tris-HCl, pH 8.2, 150 mM NaCl, with 5 mM CaCl 2 . To demonstrate specific protease activities, samples were preincubated for 30 min with class-specific inhibitors. These included 1 mM PMSF (Sigma; 100 mM in DMSO), 1 mM 1,10-orthophenanthroline (Sigma; 100 mM in DMSO), 1 mM E64 (Sigma; 100 mM in DMSO), DMSO (Sigma) at equivalent % (v/v), or 10 mM recombinant Ecotin (gift of C Craik, University of California, San Francisco, CA, USA). Activities were compared with conditioned media from cell lines with known protease activities: first-trimester cytotophoblast (CTB) cells media with MMP-2 and MMP-9 activity (CTB, a gift of Susan Fisher, University of California, San Francisco, CA, USA) and human prostate cancer line (PC3) with UPA and MMP-2, and MMP-9 activity. To detect areas of protease digestion (clear bands against a dark background), gels were stained in 0.5% (weight per volume, w/v) Coomassie blue R250 (Sigma) in 10% (v/v) acetic acid, 50% (v/v) methanol for 30 min at room temperature on a rocking platform, followed by destaining in 10% (v/v) acetic acid and 40% (v/v) methanol.
Results
Protease analysis in normal murine prostate Zymography of normal murine prostate revealed only occasional, faint bands of gelatinolytic activity, which contrasts strikingly to the activity seen in TRAMP tumors (Figure 1a ). These faint bands showed up at molecular size/weight positions consistent with the proforms of MMP-9 and MMP-2 (pro-MMP-9 and pro-MMP-2). Proforms of MMPs are readily activated by the SDS denaturation process of zymography and so display gelatinolytic activity in this assay. Overall, therefore, minimal levels of protein for these MMPs or their precursor forms are detectable in normal murine prostate.
IHC also shows minimal levels of expression of MMP-9 and MMP-2 in normal murine prostate ( Figure 3) . Stromelysin or MMP-3, on the other hand, is readily apparent in the stromal compartment of normal prostate, localizing about fibroblast or smooth-muscle cells. MMP-2 staining is also positive in scattered stromal cells in normal murine prostate, but otherwise is largely absent from the prostatic epithelial layer.
With regard to the serine protease class, moderate levels of MT-SP1 are seen in normal prostate, but only minimal levels of UPAR staining are evident in normal prostate. Surprisingly, Western analysis showed enhanced UPA production in normal dorsal-lateral prostate relative to later stages of TRAMP prostate (Figure 4a) . In fact, a gradual decrease in UPA expression with tumor progression was indicated. MT-SP1 and MT1-MMP are not readily detectable in normal murine prostate by Western, although MT-SP1 did appear to be present by IHC to some degree and localized to the epithelial layer.
Fluorogenic substrate assays were also performed on normal murine prostatic tissue. These studies showed that low-to-moderate levels of cysteine protease activity (primarily cathepsin B) are present in normal murine prostate ( Figure 5 ).
Proteases in early TRAMP tumors
In comparison to normal prostate, significantly more intense bands of activity are seen in gelatin zymography of early TRAMP prostate/tumor extracts (Figure 1 ). The major band at B98 kDa is consistent with pro-MMP-9, but less prominent bands of pro-MMP-2 are also seen (Figure 1b) . IHC for MMP-9 also indicates a significant increase and diffuse distribution of this protease throughout the prostatic gland of early TRAMP. The antibody employed for this staining cannot distinguish pro-MMP-9 from its activated-form, but the zymographic analysis indicates that the inactive species is the major form present in early TRAMP tumors. Western blotting confirmed the identity of this B98 kDa band as pro-MMP-9 (data not shown). A different MMP, Patterns of protease production RA Bok et al matrilysin (MMP-7), shows focal areas of increased expression by IHC (Figure 3 ), as do certain serine protease members, MT-SP1 and UPAR. The areas of increased staining for these proteases appear to correspond to niduses of epithelial transformation/hyperproliferation, supporting the supposition that upregulation of certain proteases is concomitant with tumor development. Western analysis of early TRAMP tumor extracts indicates that expression of a membrane-type MMP, MT1-MMP, is increased relative to its level in normal prostate (Figure 4e ). The serine protease UPA (another membrane-localized protease), in contrast, shows decreased expression in early TRAMP tumors relative to normal prostate. The respective trends in expression level continue into late TRAMP for these two proteases (see below).
Fluorogenic substrate analysis for cysteine protease activity in early TRAMP revealed a level of activity for this class of protease that is very similar to that seen in normal murine prostate ( Figure 5 ). By use of the selective inhibitor CA074, the most prominent component of this cysteine protease activity was shown to be cathepsin B (B80%). Therefore, cathepsin B activity in particular or cysteine protease activity in general does not appreciably increase in the early stages of TRAMP tumor development.
Proteases in late TRAMP tumors
In advanced or late TRAMP tumor tissues, a most striking finding was that the activated forms of the major MMPs (MMP-9 and MMP-2) predominate in zymographic analysis (Figure 1b) . There is therefore a clear shift from the latent, proform in early TRAMP to the active protease in late TRAMP, especially with respect to MMP-9. Figure 2 shows zymography of LN specimens from various advanced TRAMP mice. These dissected LNs were all abnormally enlarged and easily identifiable at necropsy, indicating pathological involvement. As with primary prostate tumor extracts, a general upregulation of protease activity is seen. Pro-MMP-9 and activated-MMP-2 bands appear prominently in most of the metastatic LN specimens, but the most notable band of increased intensity corresponds to a o50 kDa species, which is a molecular size suggestive of UPA. Analysis of these same specimens in casein-plasminogen zymograms, along with Western analysis of LN metastases from other advanced TRAMP animals (see Figure 4b ), substantiated this identification. A fair amount of heterogeneity is seen between the different TRAMP LN specimens. This may reflect, in part, the contribution of inflammatory reactions in the involved LNs. It should be mentioned that gelatin zymography reveals only a 
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RA Bok et al certain number of metalloproteases, that is, those with gelatinolytic activity, so other MMPs (such as MT1-MMP) could be present and just not detected under these assay conditions. By IHC, the pattern of staining for MMP-9 becomes more diffuse in advanced tumor lesions and appears to be present on or around both stromal and tumor elements in the anaplastic tissue ( Figure 3, bottom panel) . MMP-2 staining, in contrast, appears to be localized to the stroma in advanced TRAMP tumor. This is consistent with previous reports on the localization of this MMP in other tumor types. 16 Similar to MMP-9, the serine protease MT-SP1 displays diffuse staining over both epithelial and stromal components in advanced TRAMP. For UPAR, small but distinct foci of staining are seen in advanced TRAMP tumor-similar to the pattern seen in early TRAMP, but more limited in size. These could represent foci of inflammatory cell infiltrates, but morphology of the cells in these foci is not obviously different from adjacent tumor cells. No expression of MMP-3 could be detected by IHC in advanced TRAMP tumor, even in stromal elements, indicating downregulation of this particular MMP in late-stage disease.
By Western analysis, UPA appears to decrease further in expression and is largely absent from advanced tumors in late TRAMP mice (Figure 4a ). MT-SP1 was readily detectable in late TRAMP tumor extracts by Western blotting (Figure 4c ), corroborating the IHC findings for this membrane-tethered protease. MT1-MMP, which was minimally expressed in normal murine prostate and moderately expressed in early TRAMP, shows continued increased expression in late TRAMP tumor by Western analysis (Figure 4e) . Interestingly, UPAR, the GPI-membrane anchored receptor for UPA, shows a significant shift in molecular weight form in late TRAMP (Figure 4b ). The size of the major UPAR antigen detected by Western corresponds well to the previously reported alternative transcript for murine UPAR, termed muPAR2, 17 and is probably a secreted variant. Fluorogenic substrate analysis of late and early TRAMP primary prostate tumors and involved SV specimens showed that cysteine protease activity is about 10-fold higher than serine protease activity (data not shown). A comparison of normal, early TRAMP and late TRAMP prostate specimens (see Figure 5) indicates that, while overall cysteine protease activity is not enhanced in early TRAMP tumors relative to normal, cysteine protease activity is significantly elevated in late TRAMP tumors (B2.5-fold). In late TRAMP tissue, as in normal and early TRAMP, 80% of this activity is attributable to cathepsin B, with 20% attributable to cathepsin-L-like proteases.
Discussion
The TRAMP transgenic mouse is an autochthonous model for adenocarcinoma of the prostate, which reasonably recapitulates major features of human prostate cancer. Histological hallmarks, similar to those seen in the human gland, ranging from early prostatic intraepithelial neoplasia (PIN) like lesions to well-differentiated carcinoma to poorly differentiated carcinoma, have been identified in this animal model. For these initial studies, we focused on a few easily distinguishable stages of disease to evaluate broadly the changes in several different classes of protease. The data, obtained by various enzymatic and antigen detection techniques from the different stages and tissues, are organized and summarized in Table 1 . Our investigations reveal a significant increase of functionally active proteases, in a sequential, nonlinear pattern across time, for several categories of protease. However, a progressive decline in certain proteases is also evident. A general upregulation of proteolytic activity in tumors has been appreciated for decades. 18 However, in vivo investigations of changes in protease expression during prostate tumor progression have been lacking. Our analysis in TRAMP also reveals a general upregulation of proteolytic activity during prostate tumor progression. Members within the MMP, serine protease, and cysteine protease classes are all increased in prostate tumors from this murine model. However, some distinct phases in the upregulation of certain proteases, as lesions progress from early, well-differentiated to late, undifferentiated masses, are seen. Inactive or proforms of the major MMPs (MMP-9 and MMP-2) are substantially increased in early TRAMP tumor specimens, but their activated forms predominate mainly in late TRAMP tumors. Similarly, cysteine proteases, as detected by functional fluorogenic substrate assays, display sharp increases in levels of activity in the more advanced TRAMP tumors. These findings indicate an initial buildup of inactive precursors in the early tumor stage, with a subsequent cascade of activation in late tumors, for these major classes of proteases.
At the same time, distinct instances of downregulation are also evident, for example, MMP-3 or stromelysin. The latter finding could be reflective of a tumor-suppressive role for this particular MMP in prostatic carcinoma. Indirect evidence for a tumor-suppressive function of stromelysin-related proteases has been reported. 19 Alternatively, MMP-3 may be important only in very early phases of tumor initiation, as was suggested in studies of a murine mammary carcinoma model by Sternlicht et al. 20 UPA activity also appears to decline in advanced, anaplastic primary tumors, although it appears substantially increased in metastatic LN deposits. These results suggest distinct roles for this plasminogen activator in the metastatic vs primary tumor growth process. The importance of increased UPA in the metastatic process for prostate cancer has also been suggested by other rodent model studies. 11 In other instances, alternative transcription products of a protease factor may come into play, for example, the lower molecular weight form of UPAR detected on Western. Perhaps such a shift in expression to a smaller, soluble form of this protease receptor explains the shift to more limited, punctate staining seen by IHC in advanced TRAMP tumor. The major, low molecular weight species of UPAR seen in advanced TRAMP tumor extracts by Western blotting suggests that the alternative spliced transcript for UPAR is more abundantly expressed in later stages of prostate tumor development. This alternative spliced variant probably corresponds to a secreted, non-cell-surfaceassociated form of UPAR. 17 This observation in the transgenic mouse model is consistent with the recent reports of Miyake et al, 10 who found significant correlations between serum levels of UPAR/UPA and metastases and survival in PCA patients. In prostate and genitourinary physiology more broadly, the serine proteases appear to be a very important class of protease. This probably reflects the secretory function of the gland. Urokinase, one of the best studied plasminogen activators, was first isolated from urine. PSA, a kallikrein-like serine protease, is a remarkably specific prostate secretory product and has been validated as a diagnostic and prognostic marker for PCA.
Of particular interest, especially with regard to drug targeting, is our observation that certain membranebound proteases appear prominently and early in prostatic carcinoma relative to normal prostate. MT-SP1 and MT1-MMP are both proteases with classical, hydrophobic transmembrane domains. Their surface localization has been confirmed by immunofluorescent staining 15 and indicates a function in upstream, immediately perimembrane proteolytic events (see Figure 6 ). Several members of the membrane-associated proteases-MT-SP1, MT1-MMP, and UPAR/UPA-are either already present or upregulated early in the tumor development process in TRAMP. As these are all activators of other proteases in the pericellular/extracellular environment, their elaboration early in the transformation process may be important temporally for the subsequent wave of metalloprotease and cysteine protease activity seen in advanced tumors. MT1-MMP is a known activator of pro-MMP-2, and a coordinated expression of these two proteins has been demonstrated Patterns of protease production RA Bok et al in follicular development and ovulation and suggested in one study in prostate cancer. 21 Various endogenous protease inhibitors undoubtedly contribute to the regulation of these activations, and their temporal and spatial distributions during tumor development need to be sorted out in future studies.
Thus, a diverse array of alterations in protease expression and function can be found across different classes of proteases during prostate tumor progression in TRAMP. These studies indicate an amplification process and identify potential protease targets in prostate cancer progression, underscoring the value of transgenic animal models for dissecting temporal, biochemical aspects of tumor progression. Patterns of protease production RA Bok et al
